Prognostic value of EANO-ESMO classification of leptomeningeal metastases confirmed

Classification according to the EANO-ESMO guidelines adds prognostic value to the diagnosis of patients with leptomeningeal metastases (LM), a study has shown.

“LM affects 10% of patients with metastatic solid tumors, and median overall survival (OS) is about 2 to 6 months” said Dr Emilie Le Rhun of Zurich University Hospital in Zurich, Switzerland.

The EANO-ESMO (European Association of Neuro-Oncology and European Society for Medical Oncology) classification system is based on:

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.